Project FLYSYN-101

Basic data

Title:
FLYSYN-101
Duration:
01/02/2017 to 31/07/2019
Abstract / short description:
Phase Ib/IIa study to evaluate the safety, tolerability and preliminary efficacy of the Fc-optimized FLT3 antibody FLYSYN for the treatment of acute myeloid leukemia patients with minimal residual disease

Involved staff

Managers

Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Other Faculty of Medicine facilities
Faculty of Medicine
University of Tübingen

Funders

Tübingen, Baden-Württemberg, Germany
Help

will be deleted permanently. This cannot be undone.